Form 4: Vaxcyte CFO Sells Shares Under 10b5-1 Plan

Vaxcyte, Inc. reports that President and CFO Andrew Guggenhime sold 10,000 shares of common stock under a pre-arranged trading plan.

Summary

• Andrew Guggenhime, President and CFO of Vaxcyte, Inc., executed a transaction on July 6, 2026.
• He acquired 10,000 shares of common stock at a price of $5.35 per share.
• Concurrently, he disposed of 7,913 shares at a weighted-average price of $57.157 and 2,087 shares at a weighted-average price of $57.764.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on March 4, 2026.
• Following these transactions, Guggenhime beneficially owns 106,482 shares directly and 61,850 shares indirectly through ALG 2025 GRAT HOLDINGS LLC.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by a key executive, despite the transaction being conducted under a pre-arranged 10b5-1 plan.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-sensitive sales.
• The acquisition of 10,000 shares at a lower price ($5.35) suggests potential exercise of stock options or a similar equity award.

Negatives

• A significant number of shares (10,000) were sold by a key executive, which could be perceived negatively by the market.
• The sale of shares at prices significantly higher than the acquisition price ($57.157-$57.764 vs. $5.35) represents a substantial profit-taking event for the executive.

Risks

• The sale of a large number of shares by an executive could signal a lack of confidence in near-term stock performance, although it was executed under a 10b5-1 plan.
• Indirect beneficial ownership through a GRAT and LLC introduces complexity in understanding ultimate beneficial ownership and control.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026.
• The price reported is a weighted-average price. The shares were sold at prices ranging from $56.595 to $57.59.
• The price reported is a weighted-average price. The shares were sold at prices ranging from $57.61 to $58.32.
• The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that insider sales, even under Rule 10b5-1 plans, are closely watched by investors. While these plans are designed to mitigate concerns about insider trading, significant sales by executives can still influence market perception, especially in the biotechnology sector where stock price can be volatile and heavily influenced by clinical trial results and regulatory approvals.

Stakeholder Impact

• Shareholders may interpret the sale of shares by the CFO as a potential signal, although the 10b5-1 plan mitigates concerns about opportunistic selling.
• Employees may observe insider transactions as an indicator of company outlook.

Next Steps

• The reporting person will provide full information regarding the number of shares sold at each separate price upon request to the SEC, the issuer, or a security holder of the issuer.

Key Dates

Recommendation

The filing reports an insider sale under a 10b5-1 plan, which is a routine event for executives managing their personal portfolios. While a sale of this magnitude by a CFO can be a point of observation, the pre-planned nature of the transaction under Rule 10b5-1 suggests it's not necessarily a reflection of immediate negative sentiment towards the company's prospects. Therefore, a 'hold' recommendation is appropriate, pending further company-specific news or performance data.

Keywords

Vaxcyte, PCVX, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Andrew Guggenhime, President and CFO, Beneficial Ownership, Stock Options